Preliminary data from the randomized, controlled Phase II/III FACT trial (Fosbretabulin in Anaplastic Cancer of the Thyroid) suggest that fosbretabulin (branded as Zybrestat in the US), a vascular-disruptive agent, extended overall survival in patients with anaplastic thyroid cancer compared to carboplatin and paclitaxel. However, the study involved only 80 patients, less than half of the intended 180.
In a 2009 study, fosbretabulin failed to out-perform infusion of single agent paclitaxel.
The FDA has granted fosbretabulin disodium orphan drug designation for the treatment of anaplastic thyroid cancer, medullary thyroid cancer and stage IV papillary or follicular thyroid cancer.
Fosbretabulin is believed to have two mechanisms of action: it binds to tubulin dimers in the cell which arrests mitosis, and it also disrupts a specific signalling pathway in the cell. The end result is the collapse of tumor vasculature, or the growing network of blood vessels in a tumor.
CANCER TYPE(S)
Thyroid cancer. According to SEER statistics from the National Cancer Institute, over 44,000 new cases of thyroid cancer will be diagnosed in 2010 and almost 1,700 will die from the disease.
TREATMENT TYPE(S)
Combination therapy
WHERE WAS THIS STUDY PUBLISHED?
This study has been presented as an abstract at the International Thyroid Congress. It has not been subjected to peer review and therefore its results should be considered preliminary only.
Source
HemOncToday
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
